Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis

R P Moseley; A G Davies; R B Richardson; M Zalutsky; S Carrell; J Fabre; N Slack; J Bullimore; B Pizer; V Papanastassiou

doi:10.1038/bjc.1990.345

Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis

Br J Cancer. 1990 Oct;62(4):637-42. doi: 10.1038/bjc.1990.345.

Authors

R P Moseley¹, A G Davies, R B Richardson, M Zalutsky, S Carrell, J Fabre, N Slack, J Bullimore, B Pizer, V Papanastassiou, et al.

Affiliation

¹ Department of Neurosurgery, Frenchay Hospital, Bristol, UK.

Abstract

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Bone Marrow / radiation effects
Cause of Death
Humans
Injections, Spinal
Iodine Radioisotopes / administration & dosage*
Iodine Radioisotopes / adverse effects
Iodine Radioisotopes / therapeutic use
Meningeal Neoplasms / mortality
Meningeal Neoplasms / therapy*
Meningitis / mortality
Meningitis / therapy*
Pilot Projects
Survival Rate

Substances

Antibodies, Monoclonal
Iodine Radioisotopes